How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center

被引:30
作者
Kamangar, Faranak [1 ,2 ]
Isip, Leah [1 ]
Bhutani, Tina [1 ]
Dennis, Madison [1 ]
Heller, Misha M. [1 ,3 ]
Lee, Eric S. [1 ,4 ]
Nie, Hong [5 ]
Liao, Wilson [1 ]
机构
[1] Univ Calif San Francisco, Dept Dermatol, Psoriasis & Skin Treatment Ctr, San Francisco, CA 94118 USA
[2] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA
[3] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
[4] Univ Nebraska, Med Ctr, Coll Med, Omaha, NE USA
[5] Ernest Gallo Clin & Res Ctr, Emeryville, CA USA
关键词
psoriasis; biologics; education; barriers; cost; compliance; QUALITY-OF-LIFE; IMPACT; CARE; DERMATOLOGY; THERAPIES; GUIDELINES; MANAGEMENT; ARTHRITIS; EFFICACY; MODERATE;
D O I
10.3109/09546634.2011.631979
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The availability of new biologic agents for the treatment of psoriasis provides hope for improved quality of life outcomes. However, the way patients come to use biologics, the potential barriers they encounter, and their attitudes towards using these medications are still not well studied. Here, we conducted a survey of 106 psoriasis patients at an academic medical center to discern patient attitudes towards biologics. We found that most patients learn of biologics through their physician and perform follow-up research using the Internet. Most patients did not find it difficult to make the decision to start a biologic. Difficulty in obtaining biologics was associated with age less than 55 (p = 0.01), lower income level (p = 0.007), and lack of insurance (p = 0.04). Patients were found to have high satisfaction and compliance rates on biologics. Of patients who missed a dose of their biologic, this was mainly due to logistical reasons such as not having the medication or forgetting to take it, rather than being depressed or overwhelmed. Patients with lower income levels had increased cut backs in personal expenses due to co-payments (p = 0.001). Among respondents, the mean annual out-of-pocket expense for a biologic was $557.12 per year, with a range of $0-7000.
引用
收藏
页码:13 / 24
页数:12
相关论文
共 16 条
[1]   Long-term efficacy of biologics in dermatology [J].
Castelo-Soccio, Leslie ;
Van Voorhees, Abby S. .
DERMATOLOGIC THERAPY, 2009, 22 (01) :22-33
[2]   The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics [J].
Driessen, R. J. B. ;
Bisschops, L. A. ;
Adang, E. M. M. ;
Evers, A. W. ;
van de Kerkhof, P. C. M. ;
de Jong, E. M. G. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (06) :1324-1329
[3]   Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy [J].
Finlay, AY ;
Ortonne, JP .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 (05) :310-320
[4]   Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics [J].
Gottlieb, Alice ;
Korman, Neil J. ;
Gordon, Kenneth B. ;
Feldman, Steven R. ;
Lebwohl, Mark ;
Koo, John Y. M. ;
Van Voorhees, Abby S. ;
Elmets, Craig A. K. ;
Leonardi, Craig L. ;
Beutner, Karl R. ;
Bhushan, Reva ;
Menter, Alan .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (05) :851-864
[5]  
Gupta MA, 1998, BRIT J DERMATOL, V139, P846
[6]   Use of biological agents in patients with moderate to severe psoriasis -: A cohort-based perspective [J].
Jones-Caballero, Maria ;
Unaeze, Jane ;
Penas, Pablo F. ;
Stern, Robert S. .
ARCHIVES OF DERMATOLOGY, 2007, 143 (07) :846-850
[7]   The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis [J].
Katugampola, R. P. ;
Lewis, V. J. ;
Finlay, A. Y. .
BRITISH JOURNAL OF DERMATOLOGY, 2007, 156 (05) :945-950
[8]  
Krueger G, 2001, ARCH DERMATOL, V137, P280
[9]   The Burden of Psoriasis and Barriers to Satisfactory Care: Results from a Canadian Patient Survey [J].
Mahler, Ronald ;
Jackson, Christine ;
Ijacu, Horia .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2009, 13 (06) :283-293
[10]   The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy [J].
Menter, A .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2004, 8 :20-25